Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 10/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 8/20 | 1.00 |
| ▸ | ALOX5AP | P20292 | 7/20 | 1.00 |
| ▸ | PTGES | O14684 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503001 | 1.00 | PTGES2 (1.00) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL1193211 | 0.92 | ALOX5 (0.85) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL9458320 | 0.92 | PTGES2 (0.85) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL16857038 | 0.90 | ALOX5 (1.00) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL23270728 | 0.90 | PTGES2 (0.81) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL30181525 | 0.90 | PTGES2 (0.81) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL14037078 | 0.90 | ALOX5 (0.81) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL9457522 | 0.90 | PTGES2 (1.00) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL13447685 | 0.90 | ALOX5 (0.81) | PTGES2ALOX5ALOX5APPTGESMEN1 | |
| SCHEMBL9188781 | 0.89 | ALOX5 (0.81) | PTGES2ALOX5ALOX5APPTGESMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739297-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| WO-2025012669-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012152-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| CN-115449860-B | Nickel-gold electroplating liquid for ceramic substrate and electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| CN-115627505-B | Pulse cyanide-free gold electroplating liquid and electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115778947-A | Application of MK-886 in preparation of medicines for preventing or treating myocardial ischemia-reperfusion injury | 首都医科大学附属北京朝阳医院 | 2023-03-14 | — | — | CN | claimed |
| CN-115627505-A | Pulse cyanide-free gold electroplating solution and electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-115449860-A | Nickel-gold electroplating solution for ceramic substrate and electroplating process thereof | 深圳市创智成功科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-3999098-A1 | METHODS OF TREATING PAIN | Yeda Research and Development Co. Ltd (IL) | 2022-05-25 | — | — | EP | claimed |
| US-20220133701-A1 | METHODS OF TREATING PAIN | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-05-05 | — | — | US | claimed |
| EP-3638807-B1 | MIRNA-574-5P AS A BIOMARKER FOR STRATIFICATION OF PROSTAGLANDIN E-DEPENDENT TUMORS | FRAUNHOFER GES FORSCHUNG (DE) | 2022-03-30 | — | — | EP | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4739300-A1 | MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-2609932-B1 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11235112-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11229614-B2 | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGES2 251/4885ALOX5 302/4885ALOX5AP 139/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGES2 251/4885ALOX5 302/4885ALOX5AP 139/4885 |
| US-11229614-B2 | Supramolecular hydrogel applications to the carotid bodies to treat hypertension and sleep apnea in obesity | TRPM7, TRPC7, TRPM4 | PTGES2 3467/4885ALOX5 2666/4885ALOX5AP 2002/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | PTGES2 421/4885ALOX5 600/4885ALOX5AP 875/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PTGES2 251/4885ALOX5 302/4885ALOX5AP 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.